VIFOR PHARMA INVESTOR PRESENTATION

Page created by Chris Parsons
 
CONTINUE READING
VIFOR PHARMA INVESTOR PRESENTATION
MARCH 2021

             VIFOR PHARMA

             INVESTOR PRESENTATION
LEADING PORTFOLIO IN TARGET THERAPY AREAS

                                            Iron
                                                                                                                  Nephrology                                                           Cardio-renal
                                            deficiency

Commercial
 products
                                                                                                                                                               2

                                                                                                                         3                               4

                                                                                                          Rayaldee®5                       Avacopan6
   Pipeline                                        VIT-27631                                                             KorsuvaTM 7
   products                                                                                               Vadadustat8                       ANG-37779

1) Restriction of iron availability, i.e. for treating non-transfusion-dependent thalassemia or sickle cell disease 2) Licensed from F. Hoffmann-La Roche AG 3) Licensed from Pfizer Inc.
4) Joint commercialisation agreement with Janssen Pharmaceuticals Inc. 5) Licensed from OPKO Health, Inc. 6) Licensed from ChemoCentryx, Inc. 7) Licensed from Cara Therapeutics, Inc.
8) Licensed from Akebia Therapeutics, Inc., subject to certain conditions and limited to the US dialysis market 9) Licensed from Angion Biomedica Corp.

MARCH 2021                                                                                                                                                                                            2
VIFOR PHARMA STRATEGIC FOCUS
THREE AREAS AS BASIS FOR FUTURE GROWTH

                                        Global market leader
             1
                     Iron Deficiency    High unmet medical need
                                        Ferinject®: defined by manufacturing process

                 2
                        Nephrology

             3
                     Cardio-Renal

MARCH 2021                                                                              3
IRON DEFICIENCY – MARKET OVERVIEW
DRIVING OVERALL MARKET GROWTH

                   2014                                                                           2017                                                2020

                                   36%
                     1’924                                                                         2’633                 43%                          3’392   46%
                    CHFm                                                           57%            CHFm                                          54%   CHFm
           64%

      Ferinject®/Injectafer®, Venofer® and Maltofer®
Source: quarterly IQVIATM MIDAS® panel, GERS, Insight Health, DLI, moving annual total Q4-2020. Average 2020 exchange rates have been applied

MARCH 2021                                                                                                                                                          4
IRON DEFICIENCY – FERINJECT®/INJECTAFER®
STRONG REBOUND AFTER DECREASE IN RESTRICTIONS
NET SALES EVOLUTION
In CHF million, % at CER                             Q1: Growth compared to prior period
180                                                   in line with expectations
                                -26%          -2%
                  +26%                 +16%          Q2: Heavily impacted by COVID-19
150                                                   measures during first wave

120                                                  Q3: Immediate and strong return to
                                                      pre-COVID 19 growth with easing
 90                                                   restrictions in most countries
                                                     Q4: 2nd wave less impactful with
 60
                                                      better prepared healthcare system
 30                                                  Conclusion:
                                                      Ferinject®/Injectafer® expected to
   0                                                  be back to pre-COVID-19 growth
                     Q1         Q2      Q3    Q4      with easing lockdown measures
  2019     2020
CER = constant exchange rates

MARCH 2021                                                                                  5
IRON DEFICIENCY – FERINJECT® INDICATIONS
INDICATIONS SPLIT DRIVEN BY REGIONAL FOCUS

CAGR
’16-201                              40%                          40%

                                                                                                      40%

Sales                                                                                                                                                         26%
share by                      20%                           20%
indication                                17%                                             16%                           15%
                                                                                                                                                        12%
                                                                                                                                     9%                                9%             9%
                                                                         3%                                                                                                  4%
                                                                                                                                                                                           1%

                             Patient blood                  Heart failure                   Gastro-                     Nephrology                      Oncology /   Women’s health    Other
                             management                                                    enterology                                                   Hematology
                                                                                                           EU4 and the UK                        US

1) Pre-COVID-19 year-over-year growth rate as per end of Q1 2020
Source: quarterly IQVIATM MIDAS® panel, GERS, Insight Health, moving annual total Q3-2020 in 100mg equivalents; EU4: Germany, France, Italy and Spain

MARCH 2021                                                                                                                                                                                      6
1

    IRON DEFICIENCY – FERINJECT® PBM1 EUROPE
    MAJOR GROWTH OPPORTUNITY
    PATIENT DROP-OFF – EU4 AND THE UK
                                            135K
                                                                           221K
                                                                                                370K
                                                                                                                                                   PBM strongly supported by
                                                                                                                                                    World Health Organization

                                                                                                                                                   Estimated savings per patient
                                                                                                                                                    of CHF 850 vs usual care2
             1’933K
                                                                                                                                                   Additional real world
                                                                                                                    1’207K                          evidence data expected in
                                                                                                                                                    2021

    With iron deficiency              Other i.v. iron                   Ferinject®         Transfusion             Not treated

    Source: Vifor Pharma analysis, 2019, EU4: Germany, France, Italy and Spain       1) Patient Blood Management       2) Froessler B, et al. Risk Manag Health Policy 2018;11:77–82;

    MARCH 2021                                                                                                                                                                          7
VIFOR PHARMA STRATEGIC FOCUS
THREE AREAS AS BASIS FOR FUTURE GROWTH

             1
                     Iron Deficiency

                                        Establish leadership position
                 2
                        Nephrology      Fast growing market
                                        Leverage unique partnership

             3
                     Cardio-Renal

MARCH 2021                                                               8
NEPHROLOGY – PORTFOLIO OVERVIEW
CONTINUING TO ESTABLISH LEADERSHIP POSITION

Nephrology
revenue
                                                                                                                                                                              Upcoming launches
                          Creation of                                    launch 2015
                           VFMCRP
                            in 2010
                                                                                                              launch 2018

                              Initial portfolio                                                                                      Portfolio expansion
                                  1                1                                3
                                                                                         Avacopan2        6        KorsuvaTM 2 7           KorsuvaTM 2 7 expansion
Nephrology                                                                                                                                                                                   Exploring BD&L
                                                                               4
portfolio                                                                                                                                                                                     opportunities
                                                                                        Rayaldee® 2 5              Vadadustat2 8                  ANG-37772 9

                               2010                                           2015                                                         2020                                                        2025

1) Sales in chronic kidney disease 2) Pipeline products 3) Licensed from F. Hoffmann-La Roche AG 4) Licensed from Pfizer Inc. 5) Licensed from OPKO Health, Inc. 6) Licensed from ChemoCentryx, Inc.
7) Licensed from Cara Therapeutics, Inc. 8) Licensed from Akebia Therapeutics, Inc., subject to certain conditions and limited to the US dialysis market 9) Licensed from Angion Biomedica Corp.

MARCH 2021                                                                                                                                                                                                    9
NEPHROLOGY OPPORTUNITIES
LARGE AND GROWING MARKET WITH HIGH UNMET MEDICAL NEED

         COMMERCIAL                  PIPELINE                 BD&L OPPORTUNITIES

                                  Uremic pruritus            CKD progression drivers
         Iron deficiency     ANCA associated vasculitis
                                                           CKD associated complications
             Anaemia       Secondary hyperparathyroidism
 Diabetic kidney disease     Cardiac surgery associated    Dialysis related complications
    Hyperphosphatemia            acute kidney injury
                               Delayed graft function           Acute kidney injury
         Hyperkalemia
                                       C3G                        Transplantation

MARCH 2021                                                                                  10
NEPHROLOGY – PARTNERSHIP WITH FMC1
UNIQUE EXPERTISE AND PATIENT ACCESS

                STRONG IRON AND PHARMA EXPERTISE                     55%
                                                                    Stake
     Clinical development
     Manufacturing, regulatory and market access experiences
     Global commercial presence
                                                                            Global leadership in nephrology through:
                                                                             Combination of strengths
                                                                             Optimal sourcing of innovation
                                                                             Access to patient data & faster clinical trial execution
                            GLOBAL LEADER IN DIALYSIS                        Improving outcomes via treatment algorithms

          ~350’000                 >52 million            >4’000
             patients          dialysis treatments p.a.   clinics

                                                                     45%
                                                                    Stake

1) Fresenius Medical Care

MARCH 2021                                                                                                                               11
VIFOR PHARMA STRATEGIC FOCUS
THREE AREAS AS BASIS FOR FUTURE GROWTH

             1
                     Iron Deficiency

                 2
                        Nephrology

                                        Natural portfolio extension
             3
                     Cardio-Renal       Strong momentum in Europe
                                        Significant opportunity with Veltassa®

MARCH 2021                                                                        12
CARDIO-RENAL – PATIENT POPULATION
NATURAL EXTENSION OF OUR THERAPY AREA FOCUS

                                              CARDIO-RENAL PATIENTS

                                       Reduced kidney                Reduced heart
                                               function              function
                                       associated with               associated with
                                      increased risk of              increased risk of
                                      heart impairment               renal impairment

                                                                                                              HEART FAILURE
                                                      Stage IV     Stage III             Stage II   Stage I
  NEPHROLOGY
               Stage I   Stage II      Stage III      Stage IV   Stage V

                                    NEPHROLOGISTS AND CARDIOLOGISTS
                                        ALREADY TARGETED TODAY

MARCH 2021                                                                                                                    13
CARDIO-RENAL – FERINJECT® EUROPE
AFFIRM-AHF STUDY SHOWED STRONG CLINICAL BENEFITS
TOTAL HEART FAILURE HOSPITALISATION
                                           100
                                                     Rate ratio (95% CI): 0.74 (0.58–0.94); p=0.013
 Mean cumulative events per 100 patients

                                                                                                                         26% reduction in heart failure
                                            80
                                                                                                                          re-hospitalization

                                            60
                                                                                                                         Reduction irrespective of anemia status
                                                                                                                         Strengthening of ESC guideline expected
                                            40                                                                            in 2021
                                                                                                                         Market opportunity over CHF 500m in
                                            20
                                                                                                                          Europe

                                             0
                                                 0      4   8   12     16 20 24 28 32 36 40              44   48   52
                                                                      Time since randomization (weeks)

                                           Ferinject®       Placebo

MARCH 2021                                                                                                                                                          14
CARDIO-RENAL – INJECTAFER® US
MAJOR UNADDRESSED GROWTH OPPORTUNITY
HFrEF1 PATIENT DROP-OFF – US
                                        410K
                                                                                                                     Injectafer® label extension based on
                                                                                                                      FAIR-HF & CONFIRM-HF in 2021/22

                                                                                                                     Further label and guideline
                                                                      21K                    17K                      strengthening following HEART-FID
                                                                                                                      study
           948K

                                                                                                                     US market opportunity over USD 1
                                                                                                        500K          billion

With iron deficiency                  Other iron             Other i.v. iron             Ferinject®   Not treated
   anaemia (IDA)

1) Heart failure with preserved injection fraction
Source: interviews with US HF specialists, ZS analysis on claims, ATU research, scientific papers

MARCH 2021                                                                                                                                                15
CARDIO-RENAL – VELTASSA®
SIGNIFICANT OPPORTUNITY WITH EXISTING PRESCRIBERS
IN-MARKET SALES – WORLDWIDE
                                                                                                                               KEY CHARACTERISTICS
        2015                                                            2020                                                    Calcium-based, non-absorbed
                                                                                                                                52-weeks data available
                                                                                                                                Acute & chronic usage

                                                       38%                                     40%                              KEY FOCUS
         172                                                             431
        CHFm                                                            CHFm                                                     Build awareness
                                                                                                                                 Establish clinical differentiation
                                                                                                                                 Improve pull-through
                                                                          22%
                                                                                                                                 DIAMOND study is significant growth
                                                                                                                                  accelerator and “differentiator”

  Veltassa®        Sodium zirconium cyclosilicate          Other potassium binders

Source: monthly IQVIATM MIDAS® panel, GERS, InsightHealth, DLI, moving annual total Q4-2020. Average 2020 exchange rates have been applied.

MARCH 2021                                                                                                                                                              16
PROVEN BD&L CAPABILITIES & STRONG PIPELINE
KEY UPCOMING LAUNCHES AND DATA READOUTS
      PRE-CLINICAL                             PHASE 1                              PHASE 2                              PHASE 3                      PRE-COMMERCIAL                      LIFE CYCLE MANAGEMENT

       NephThera                                                                                                                                                                                               HEART-FID6
     (Kidney fibrosis)                                                              VIT-2763
                                                                            (Ferroportin inhibitor)
                                                                                                                                                                                                                 DIAMOND
                                                                                 ANG-37771
                                                                                   (CSA-AKI)
                                                                                                                      ANG-37771
                                                                                                                           (DGF)
                                                                                                                                                          Rayaldee® 2

                                                                                                                                                          KorsuvaTM 3

                                                                                                                                                           Avacopan4

                                                                                                                                                          Vadadustat5

BD&L = Business development and licensing                  DGF = Delayed graft function      CSA-AKI = Cardiac surgery associated acute kidney injury
1) Licensed from Angion Biomedica Corp. 2) Licensed from OPKO Health, Inc. 3) Licensed from Cara Therapeutics, Inc. 4) Licensed from ChemoCentryx, Inc. 5) Licensed from Akebia Therapeutics, Inc., subject to certain conditions and
limited to the US dialysis market 6) Study conducted by our US partner Daiichi Sankyo

MARCH 2021                                                                                                                                                                                                                              17
AVACOPAN
NEW STANDARD OF CARE IN ANCA-AV

                       Sustain remission                                                                           Reduce glucocorticoid toxicity
         statistically superior at 52 weeks                                                                                       vs. standard of care

                                                                               Avacopan1
      Orphan and rare renal disease                                                                                                   Global rights
         around 50k patients in Europe                                                                                                   excl. US

         Approval in Europe and Japan                                                                                Potential in further indication
                                       2021                                                                                      including C3G and HS

ANCA-AV = Anti-neutrophil cytoplasmic antibody-associated vasculitis   C3G = C3 glomerulopathy   HS = Hidradenitis suppurativa
1) Licensed from ChemoCentryx, Inc.

MARCH 2021                                                                                                                                               18
KORSUVATM (CR845/DIFELIKEFALIN) INJECTION
INNOVATION IN CKD-ASSOCIATED PRURITUS

   Standard of care with poor efficacy                          ~40% of ESRD patients
         and/or unfavorable safety profile                    moderate to severe CKD-aP

                                             KorsuvaTM 1
               No approved treatment                                   Global rights
                  in the US and Europe                         excl. Japan and South Korea

       Launch in the US in end of 2021                     Leverage commercial organisation
               followed by Europe in 2022                    established presence in dialysis

1) Licensed from Cara Therapeutics, Inc.

MARCH 2021                                                                                      19
ANG-3777
EXPANDING LEADERSHIP ON THE NEPHROLOGY CHAIN

                   First small molecule                                                                       Global rights2
        hepatocyte growth factor mimetic                                                                   in DGF and CSA-AKI

                                                                                              ANG-37771
        ~110k patients with CSA-AKI                                                                        ~26k patients with DGF
           US, UK and EU4 combined                                                                        US, UK and EU4 combined

             Phase-II study in CSA-AKI                                                                    Phase-III study in DGF
                     read out in H2 2021                                                                  read out in end of 2021

DGF = Delayed graft function         CSA-AKI = Cardiac surgery associated acute kidney injury
1) Licensed from Angion Biomedica Corp.                2) Excluding China, Taiwan, Hong Kong and Macau

MARCH 2021                                                                                                                          20
VIT-2763 (FERROPORTIN INHIBITOR)
TARGETING RARE BLOOD DISORDERS

                                                        Blocks iron transport to               Mechanism similar to
                 Oral small molecule
                                                        the blood                              hepcidin

                                 BETA THALASSEMIA                                  SICKLE CELL DISEASE

Unmet need                       Transfusion burden and iron overload              Pain crisis and and organ damage

Addressable
                                 Approx. 25’000                                    Approx. 150’000
patients1

Phase-II status                  Recruitment completion expected in H2 2021        Study initiation expected in 2021

1) US and EU combined estimate

MARCH 2021                                                                                                             21
2020 PERFORMANCE
OVERALL PORTFOLIO RESILIENT
                                Net sales growth at constant exchange rates

Venofer®                                                                 8.4%

Maltofer®                                                               7.8%

Velphoro®                                                     3.6%

Ferinject®/Injectafer®                                      3.0%

Mircera®/Retacrit®                                         2.5%

Veltassa®                           -5.1%

Net sales                                                     3.7%

                         -10%           -5%        0%             5%       10%

MARCH 2021                                                                       22
P&L OVERVIEW (IN CHF MILLION)
EBITDA GROWTH OF 35.7% ON A COMPARABLE BASIS
                                                                                   FY                         FY                     %∆ vs.
                                                                                  2019 1                     2020                     2019                    Other income increase driven by
Net Sales                                                                         1’725.0                    1’705.6                   -1.1%                   partnering activities for Ferinject®,
Other Income                                                                         37.0                       96.4                +160.5%                    Veltassa® and Velphoro® as well as
Gross Profit                                                                       1’061.2                    1’100.8                    +3.7%                 disposal of non-core products
EBITDA                                                                                485.0                      575.8                 +18.7%                 EBITDA growth of +35.7% on a
Depreciation and amortization                                                        -209.1                     -284.4                 -36.0%                  comparable basis driven by cost
EBIT                                                                                  275.9                      291.4                  +5.6%
                                                                                                                                                               containment measures
Profit from continuing operations                                                     222.8                      237.6                   6.6%
Profit from discontinued operations                                                    50.9                      220.9                 334.0%                 Depreciation and amortization
Net profit before NCI                                                                 273.8                      458.6                  67.5%                  driven by CCX140 impairment of
Non-controlling interests                                                            -114.7                      -98.9                  13.8%                  CHF 56.2 million (H1 2020)
Net profit after NCI                                                                  159.1                      359.6                 126.0%
                  2
                                                                                                                                                              Profit from discontinued operations
Core EPS from continuing operations                                                      3.88                       4.99              +28.7%
                                                                                                                                                               due to disposal of OM Pharma in
                                                                                                                                                               September 2020

NCI = non-controlling interests EPS = earnings per share
1) Restated 2) Reported earnings after non-controlling interests adjusted for proportionate amortization and impairment of intangible assets of CHF 185.0 million in 2020 (2019: CHF 143.5 million)

MARCH 2021                                                                                                                                                                                            23
BALANCE SHEET OVERVIEW (IN CHF MILLION)
STRONG EQUITY RATIO OF 77.1%

                                                                             31 Dec                   31 Dec               Change vs.
                                                                              2019 1                   2020                  2019
                                                                                                                                             Cash & cash equivalents increase
 Cash & cash equivalents                                                        544.9                    730.0                 185.1          driven by OM Pharma divestment,
 Trade & other receivables                                                      471.9                    487.7                  15.8          partly offset by BD&L4 investments
 Inventories                                                                    348.6                    339.8                  (8.8)         and dividend distributions
 Financial investments & other assets                                           633.5                    896.8                 263.3
      2       3
 PPE & RoU assets                                                               351.0                    302.8                (48.2)         Financial investments increase
 Intangible assets                                                            2’584.5                  2’454.5               (130.0)          mainly driven by gain on
Assets                                                                        4’934.4                  5’211.7                 277.3          ChemoCentryx equity stake
 Current financial & lease liabilities                                             17.8                     23.0                     5.2     Intangible assets decrease mainly
 Other current liabilities                                                        523.6                    521.0                   (2.6)      driven by OM Pharma divestment
 Non-current financial & lease liabilities                                        626.5                    608.6                  (17.9)      and CCX140 impairment, partly
 Other non-current liabilities                                                     31.3                     41.5                    10.2
 Shareholders' equity                                                           3’735.3                  4’017.6                  282.3
                                                                                                                                              offset by purchase of a priority
Liabilities & shareholders' equity                                              4’934.4                  5’211.7                  277.3       review voucher for CHF 107.7
                                                                                                                                              million

1) Balance sheet as of 31 December 2019 not restated 2) Property, plant & equipment 3) Right-of-use 4) Business development and licensing

MARCH 2021                                                                                                                                                                        24
CASH FLOW OVERVIEW (IN CHF MILLION)
NET CASH POSITION OF CHF 190.6 MILLION
                                                                                                                 2020
Opening cash & cash equivalents, 1 January                                                                            544.9     Net working capital increase due to phasing
    Operating activities                                                                                           549.1         of payment from major customers and
    Net working capital                                                                                          (127.2)         planned increase in inventory
    Interest, tax & other financial payments                                                                      (19.3)
    Operating cash flow from discontinued operations                                                                21.2        Milestone and BD&L1 investments driven by
   Cash flow from operating activities                                                                             423.8         extension of the agreement with Cara
    Milestones & BD&L1 investments                                                                               (256.0)         Therapeutics, licensing of ANG-3777 and
    Capex & others                                                                                                (70.0)         acquisition of a priority review voucher
    Net proceeds from OM Pharma divestment                                                                         378.4
   Cash flow from investing activities                                                                              52.4        Investments more than offset by net
    Dividends paid                                                                                               (219.6)         proceeds from the OM Pharma divestment
    Financing & others                                                                                            (48.7)         of CHF 378.4 million
   Cash flow from financing activities                                                                           (268.4)
                                                                                                                                Dividend payments of CHF 129.6 million to
   Exchange rate effects                                                                                              (22.7)
                                                                                                                                 Vifor Pharma shareholders and CHF 90.0
Ending cash & cash equivalents, 31 December                                                                           730.0
                                                                                                                                 million to Fresenius Medical Care
    Financial liabilities2                                                                                       (539.5)
   Net debt                                                                                                        190.6
1) Business development and licensing 2) Excluding non-interest bearing financial liabilities and lease liabilities

MARCH 2021                                                                                                                                                                   25
GUIDANCE 20211

                           In 2021, at constant exchange rates, net sales are expected
                           to grow at a low-to-mid single digit rate, and EBITDA to grow
                           at a high single digit rate.

1) The COVID-19 pandemic continues to impact economic conditions and patient access to our treatments; therefore Vifor Pharma’s 2021 guidance assumes a progressive improvement of patients access to the Company’s treatments
as of H2 2021

MARCH 2021                                                                                                                                                                                                                       26
OUTLOOK 2021

                                                  Ferinject® approval in China
                                                  KorsuvaTM 1 approval in the US and filing in Europe
  MARKET ACCESS                                   Avacopan2 approval in Europe and Japan
                                                  Avacopan2 & KorsuvaTM 1 partnering in China
                                                  Vadadustat3 filing in the US by our partner Akebia Therapeutics by mid-Q2 2021

                                                  VIT-2763 phase-II initiation in sickle cell disease in H1 2021
                                                  VIT-2763 phase-II recruitment completion in beta thalassemia in H2 2021
  CLINICAL TRIALS
                                                  ANG-37774 phase-II readout in CSA-AKI in H2 2021
                                                  ANG-37774 phase-III readout in DGF in Q4 2021

  BD&L                                            At least two in-licensing deals, product acquisitions or corporate transactions

1) Licensed from Cara Therapeutics, Inc. 2) Licensed from ChemoCentryx, Inc. 3) Licensed from Akebia Therapeutics, Inc., subject to certain conditions and limited to the US dialysis market
4) Licensed from Angion Biomedica Corp.

MARCH 2021                                                                                                                                                                                     27
CONTACT INFORMATION

                                                                    Investor relations

  Colin Bond                          Julien Vignot                           Laurent de Weck
  Chief Financial Officer             Head of Investor Relations              Investor Relations Senior Manager
  Phone: +41 58 851 83 53             Phone: +41 58 851 66 90                 Phone: +41 58 851 80 95
  Email: colin.bond@viforpharma.com   Email: julien.vignot@viforpharma.com    Email: laurent.deweck@viforpharma.com

MARCH 2021                                                                                                            28
DISCLAIMER

Certain statements, beliefs and opinions in this presentation are forward-looking, which reflect the Company’s or, as
appropriate, the Company’s directors’ current expectations and projections about future events. By their nature, forward-
looking statements involve a number of risks, uncertainties and assumptions that could cause actual results or events to
differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and
assumptions could adversely affect the outcome and financial effects of the plans and events described herein. A
multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events,
performance or results to differ significantly from any anticipated development. Forward-looking statements contained
in this presentation regarding past trends or activities should not be taken as a representation that such trends or activities
will continue in the future. As a result, the Company expressly disclaims any obligation or undertaking to release any
update or revisions to any forward-looking statements in this presentation as a result of any change in expectations or any
change in events, conditions, assumptions or circumstances on which these forward-looking statements are based.
Neither the Company nor its advisers or representatives nor any of its of their parent or subsidiary undertakings or any
such person’s officers or employees guarantees that the assumptions underlying such forward-looking statements are free
from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in
this presentation or the actual occurrence of the forecasted developments. You should not place undue reliance on
forward-looking statements, which speak only as of the date of this presentation.

MARCH 2021                                                                                                                   29
You can also read